Latest Capital Markets News

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Despite sweeping changes to Capital Gains Tax announced in the 2026/27 Federal Budget, Acrux Limited’s status as a Pooled Development Fund ensures its shareholders remain shielded from these new tax rules.

NEXTDC has successfully closed the retail segment of its fully underwritten entitlement offer, securing A$480 million at A$12.70 per share. The total raise of approximately A$1.5 billion demonstrates strong investor backing ahead of the shares commencing trade on 19 May 2026.

Tamboran Resources has reported record gas flow rates from its Shenandoah South 6H well and secured US$188 million in a capital raise, positioning the company to deliver first gas in the Beetaloo Basin by Q3 2026.

Novo Resources narrowed its Q1 2026 net loss to CAD 685K, boosted cash to CAD 10.6M following a $5.9M placement, and outlined aggressive gold and antimony drilling campaigns in Australia.

ASX has appointed Anthony Attia as its next Managing Director and CEO, bringing nearly 30 years of global exchange experience to guide the company through its ongoing transformation.

Finder Energy (ASX:FDR) is advancing its KTJ Project in Timor-Leste, aiming for a final investment decision by mid-2026 and first oil production by late 2027. Ownership of the Petrojarl I FPSO and strategic alliances underpin a fast-tracked development with forecast production of up to 30,000 barrels per day.

Atlas Arteria reported a resilient 2025 with 9.3% EBITDA growth and steady toll revenue, while its Board unanimously urged investors to reject IFM’s unsolicited takeover offer, citing undervaluation and onerous conditions.

Titomic Limited is set to shift its corporate domicile from Australia to the United States through a scheme of arrangement, aiming to deepen its US defense market presence and access broader capital pools while maintaining its ASX listing.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

5E Advanced Materials secures a decade-long boric acid offtake agreement and advances boron product development, while reporting a $12.1 million quarterly loss and planning ASX delisting.

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.